Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel

Authors

  • Mahesh Paithankar Intas Pharmaceuticals Ltd, Ahmedabad, Gujarat, India
  • Mangesh Bhalekar 2Department of Pharmaceutics, AISSMS College of Pharmacy, Pune, Maharashtra, India

Abstract

Cabazitaxel (CTX), a novel taxane derivative, has proven effective in many solid tumors. It is also approved in many countries for multiple uses in solid tumors. The current marketed formulation lacks the tumor-targeting ability, and its uneven distribution in the body causes toxicity to normal tissues. Further, it is a surfactant (polysorbate 80) based micellar formulation composed of ethanol as a co-solvent to improve the solubility of CTX, which causes severe and life-threatening side effects. Hence, to avoid the problem associated with this conventional CTX formulation, the nanoparticulate drug delivery system of CTX was developed by employing the Quality by Design (QbD) approach. The CTX nanoparticulate system was developed by employing a bottom-up followed by a top-down approach. The size reduction was obtained by High-Pressure Homogenizer (HPH). The formulation optimization was done using QbD approach. Design of experiments (DoE) was used to understand the effect of various formulation and process variables on a dependent variable like particle size distribution.
The stabilizer concentration, concentration of solubilizer, HPH pressure, and passes were selected as independent factors while particle size distribution was selected as a dependent factor for evaluation. The nanoparticulate system was developed using PEG-400 as solubilizing agents, while Soya Phosphatidylcholine (SPC) was used as a surface stabilizer. Response surface plots revealed a decrease in particle size with increasing concentration of SPC and PEG 400. Similarly, a decrease in particle size with increased HPH passes and pressure was found. The optimum concentrations of SPC and PEG 400 were found to be 20% and 2.5%, respectively. 20 KPSI pressure and 5 HPH passes were derived as optimized processing parameters from DoE. The optimized formulation had a size of 43.5 nm, with PDI < 0.4. Due to its narrow particle size distribution, the formulation did not show any increase in particle size or aggregation up to 24 hours. The present research confirms the feasibility of developing the nanoparticulate system of CTX using the bottom-up followed by the top-down technique. The formulation was systematically optimized using QbD approach. The optimum concentration of PEG 400 as solubilizer and concentration of SPC as stabilizer was obtained from DoE, yielding optimum particle size and stability.

Keywords:

Cabazitaxel, Nanoparticulate system, Top-down, design of experiment, optimization

DOI

https://doi.org/10.25004/IJPSDR.2022.140115

References

Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. Journal of Controlled Release. 2010;141(3):300-2.

Lawrence XY. Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical research. 2008;25(4):781-91.

Patil KD, Bagade S, Bonde S. QbD-enabled stability-indicating assay method for the estimation of linezolid in newly developed gelatin nanoparticles for anti-tubercular therapy. Chromatographia. 2020;83(8):963-73.

Rajpoot K, Tekade M, Sreeharsha N, Sharma MC, Tekade RK. Recent advancements in solubilization of hydrophobic drugs. The Future of Pharmaceutical Product Development and Research: Elsevier; 2020. p. 109-44.

Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. International journal of pharmaceutics. 2009;377(1-2):185-98.

Savic IM, Marinkovic VD, Tasic L, Krajnovic D, Savic IM. From experimental design to quality by design in pharmaceutical legislation. Accreditation and Quality Assurance. 2012;17(6):627-33.

Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clinical Cancer Research. 2012;18(24):6574-9.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clinical Cancer Research. 2013;19(11):2973-83.

Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug design, development and therapy. 2011;5:117.

Aydin O, Youssef I, Yuksel Durmaz Y, Tiruchinapally G, ElSayed ME. Formulation of acid-sensitive micelles for delivery of cabazitaxel into prostate cancer cells. Molecular pharmaceutics. 2016;13(4):1413-29.

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of Controlled Release. 2019;293:183-92.

Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine. 2017 ;12(17):2083-95..

Junghanns J-UA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. International journal of nanomedicine. 2008;3(3):295.

Jena SK, Singh C, Dora CP, Suresh S. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. International journal of pharmaceutics. 2014;473(1-2):1-9.

Frick A, Möller H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levof loxacin. European journal of pharmaceutics and biopharmaceutics. 1998;46(3):305-11.

Miyako Y, Khalef N, Matsuzaki K, Pinal R. Solubility enhancement of hydrophobic compounds by co-solvents: role of solute hydrophobicity on the solubilization effect. International journal of pharmaceutics. 2010;393(1-2):48-54.

Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. Journal of controlled release. 2001;73(2-3):137-72.

Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and co-solvents. European journal of pharmaceutical sciences. 2006;28(1-2):7-14.

Chakraborty S, Shukla D, Mishra B, Singh S. Lipid–an emerging platform for oral delivery of drugs with poor bioavailability. European Journal of Pharmaceutics and Biopharmaceutics. 2009;73(1):1-15.

Zirar SB, Ast ier A, Muchow M, Gibaud S. Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice. European journal of pharmaceutics and biopharmaceutics. 2008;70(2):649-56.

Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, et al. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol– polysorbate 80 mixture. International journal of pharmaceutics. 2004;269(1):251-8.

Ravichandran R. Nanotechnology-based drug delivery systems. NanoBiotechnology. 2009;5(1-4):17-33.

Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics. 2019;11(3):141.

Published

30-01-2022
Statistics
Abstract Display: 601
PDF Downloads: 526
Dimension Badge

How to Cite

“Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 14, no. 1, Jan. 2022, pp. 112-21, https://doi.org/10.25004/IJPSDR.2022.140115.

Issue

Section

Research Article

How to Cite

“Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 14, no. 1, Jan. 2022, pp. 112-21, https://doi.org/10.25004/IJPSDR.2022.140115.